Clinical trial
Modulation of Gut Microbiota by Rifaximin in PD Patients
NCT03958708 is registered in ClinicalTrials.gov with Taipei Medical University Shuang Ho Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Modulation of Gut Microbiota by Rifaximin in PD Patients
- Lead sponsor
- Taipei Medical University Shuang Ho Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- May 13, 2019
- Completion date
- December 1, 2020
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.